Article Sidebar
Published:
Nov 14, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Therapeutic effect of a combination of montelukast and vitamins A and D drops in children with bronchial asthma, and its influence on quality of life
Abstract
Purpose: To investigate the efficacy of a combination of montelukast and vitamins A and D drops in bronchial asthma children, and its effect on quality of life.
Methods: Sixty bronchial asthma children from June 2018 to June 2020 were collected and randomized into study group and control group (30 cases in each group). Control group received montelukast sodium (chewable tablets), while the study group received vitamins A and D drops (capsules) plus. Clinical efficacy, lung function, serum inflammatory factors, and quality of life were evaluated and compared.
Results: Compared with control group, total treatment effectiveness was higher and the symptom remission period was shorter in the study group (p < 0.05). Post-treatment, the parameters of FEV1 and FVC increased in both groups, but higher in the study group (p < 0.05). Serum levels of CRP and IL-4 in both groups decreased after treatment, while serum IL-10 levels were significantly up-regulated. Compared with control group, the levels of these indicators were improved in the study group (p < 0.05). Post-treatment Chinese Version of Pediatric Quality of Life Asthma Specific Scale (PedSQL) score was higher than before treatment, with higher values (for all indicators) in the study group (p < 0.05).
Conclusion: The combination therapy of montelukast and vitamins A and D drops produces good clinical efficacy in children with bronchial asthma. It significantly shortens the time taken for relief of clinical symptoms, improves lung function, reduces inflammatory response, controls asthma, and improves the quality of life of the patients.
